Arca
Skip to content
Tools
Tools

VWF: von Willebrand factor

Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet- surface receptor complex GPIb-IX-V.

  • Drugs that act on it: 4
  • Approved: 3
  • In phases 1 to 3: 1
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on VWF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1
  • Other 2

Approved3

  • Von willebrand factor human
  • Caplacizumab
  • Vonicog alfa

Phase 30

    Phase 21

    • Egaptivon pegol

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Von willebrand factor humanApprovedTakeda Pharmaceuticals USAOtherExogenous proteinvon Willebrand factor exogenous protein32
      CaplacizumabApprovedSanofiAntibodyInhibitorvon Willebrand factor inhibitor3
      Vonicog alfaApprovedTakeda Pharmaceuticals USAProtein or peptideExogenous proteinvon Willebrand factor exogenous protein3
      Egaptivon pegolPhase 2Archemix Corp.OtherInhibitorvon Willebrand factor inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
      Blood Clotting Markers and Heart Ultrasound in People With Device-Detected Atrial FibrillationVon willebrand factor human—RecruitingAndreas Sjøholm-ChristensenJul 20, 2026
      Flow-Based Platelet Function Assessment Using Total Thrombus-Formation Analysis System (T-TAS) and Early Bleeding After Cardiac Surgery With Cardiopulmonary Bypass (CPB)Von willebrand factor human—Not yet recruitingHospital de la Santa creu i Sant Pau - BarcelonaJun 1, 2026
      MICROVASCULAR DAMAGE IN THROMBOTIC THROMBOCYTOPENIC PURPURAVon willebrand factor humanNot applicableActive, not recruitingFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoMay 29, 2026
      Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.Von willebrand factor humanPhase 3RecruitingCardiocentro TicinoMay 13, 2026
      Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt PlacementVon willebrand factor human—RecruitingAssistance Publique - Hôpitaux de ParisFeb 27, 2026
      Perioperative Outcomes After Neoadjuvant Therapy in Colorectal CancerVon willebrand factor human—RecruitingOsijek University HospitalFeb 20, 2026
      Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut GovernorateVon willebrand factor human—Not yet recruitingAssiut UniversityFeb 13, 2026
      An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Von willebrand factor human, Vonicog alfa—RecruitingTakedaFeb 11, 2026
      A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Vonicog alfaPhase 3RecruitingTakedaAug 19, 2025
      Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP SurvivorsCaplacizumab—Not yet recruitingUS Thrombotic Microangiopathy AllianceApr 10, 2024
      Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic PurpuraCaplacizumabNot applicableRecruitingUniversity Hospital, RouenMar 4, 2024
      A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)Vonicog alfaPhase 3RecruitingTakedaOct 17, 2022
      Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTPCaplacizumab—Active, not recruitingUniversity of CologneAug 2, 2021

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Von Willebrand disease 2
      0.82
      Von Willebrand disease 3
      0.80
      Von Willebrand disease 1
      0.79
      Von Willebrand disease type 2B
      0.71
      Hereditary von Willebrand disease
      0.68
      Von Willebrand disease type 2A
      0.67
      Von Willebrand disease type 2M
      0.65
      Von Willebrand disease type 2N
      0.65
      Cancer
      0.62
      Platelet-type von Willebrand disease
      0.61

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2021748, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P04275, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.